307. States are encouraged to incorporate criteria for toxic pollutants, based on this guidance, into their water quality standards. To date EPA has promulgated no standards for the phthalate esters.
The Water Quality Criteria Document for Phthalate Esters was prepared prior to the public release of NCI/NTP's di(2-ethylhexyl) phthalate (DEHP) bioassay results and therefore did not take into account the NCI/NTP finding that DEHP was a carcinogen in both rats and mice under the conditions of the test (1) (6) . The DEHP results heightened the concerns of the Office of Toxic Substances, as well as those of the phthalate manufacturers, over the possible human health risks of the alkyl phthalates. A program for testing for both health and environmental effects was therefore developed by the manufacturers and users and coordinated by the CMA (forming the Phthalate Esters Program Panel). A summary presentation of this program was made to the Agency in November of 1980, followed by more detailed discussions. From the start, the CMA program was reasonably comprehensive in the environmental area. However, the health effects testing proposed at that time was limited to a small group of compounds with a focus on elucidating the mechanism of action for DEHP regarding its oncogenicity. Further meetings, then, to expand the health effects testing and also to add some additional testing to the environmental effects program were held, beginning in December of 1980, and continuing up until the present.
As a final result of all of these meetings, the Agency and the CMA appear to be close to an agreement on an industry-sponsored program of testing which matches the major testing needs of the Agency. Industry's voluntary program will answer environmental effects questions relating to toxicity to aquatic organisms, environmental fate and transport and biodegradation of all fourteen identified high production alkyl phthalates and benzyl butyl phthalate. These compounds are produced in quantities near or greater than ten million pounds per year. As will be explained elsewhere in this program (7) , the CMA proposal also includes a screening program to examine the health effects issues of oncogenicity and mutagenicity for a somewhat smaller group of nine alkyl phthalates and benzyl butyl phthalate (8 
